Viromed Medical AG (XTER:VME) 3-Year EBITDA Growth Rate: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:VME Viromed Medical AG XTER:VME
22 GF Score
Price €6.35
! 2 Warning Signs
View Full Analysis

What is Viromed Medical AG 3-Year EBITDA Growth Rate?

Viromed Medical AG XTER:VME -3.79% 22 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus rates XTER:VME with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Viromed Medical AG ranks worse than 144717.66% on this metric.

Viromed Medical AG's EBITDA per Share for the six months ended in Dec. 2025 was €-0.01.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Viromed Medical AG  (XTER:VME) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Viromed Medical AG 3-Year EBITDA Growth Rate Related Terms

XTER:VME vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Viromed Medical AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viromed Medical AG 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Viromed Medical AG's 3-Year EBITDA Growth Rate falls into.


XTER:VME
22GF Score
Viromed Medical AG XTER:VME
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viromed Medical AG 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Viromed Medical AG (XTER:VME) has a 3-Year EBITDA Growth Rate of 0.00% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Viromed Medical AG and its competitors. According to the industry distribution chart, Viromed Medical AG ranks #999999 out of 691 companies in the Medical Devices & Instruments industry.
Is Viromed Medical AG's 3-Year EBITDA Growth Rate too high?
Viromed Medical AG's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Viromed Medical AG ranks #999999 out of 691 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Viromed Medical AG ranks #999999 out of 691 companies for 3-Year EBITDA Growth Rate. This places Viromed Medical AG in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Viromed Medical AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viromed Medical AG's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (XTER:VME) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Viromed Medical AG's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Viromed Medical AG (XTER:VME), the current 3-Year EBITDA Growth Rate is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viromed Medical AG Business Description

Other Exchanges VME:GermanyVME:Germany
Address Hauptstrasse 105, Rellingen, Pinneberg, SH, DEU, 25462
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score

Get the complete analysis for XTER:VME

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.35
Price